Stockscreener 앱 받기
2.15
1.83%
-0.04
전일 마감가:
$2.19
열려 있는:
$2.24
하루 거래량:
17,162
Relative Volume:
0.04
시가총액:
$4.80M
수익:
-
순이익/손실:
$-9.64M
주가수익비율:
-0.3105
EPS:
-6.9236
순현금흐름:
$-10.11M
1주 성능:
-3.59%
1개월 성능:
-25.09%
6개월 성능:
-4.44%
1년 성능:
-55.02%
1일 변동 폭
$2.15
$2.38
1주일 범위
$2.10
$2.39
52주 변동 폭
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
명칭
Gt Biopharma Inc
전화
(800) 304-9888
주소
315 MONTGOMERY STREET, SAN FRANCISCO
GTBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 417.43M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 97.32M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.03M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 개시 | ROTH MKM | Buy |
| 2021-05-24 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | B. Riley Securities | Buy |
| 2021-03-17 | 개시 | ROTH Capital | Buy |
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire
Nanobodies Market Analysis: Growth Drivers in Targeted - openPR
Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World
Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World
Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World
First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World
StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded by StockNews.com to Hold Rating - Defense World
Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World
Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World
AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World
GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire
GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - The Manila Times
GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers - StockTitan
GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection - ACCESS Newswire
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
Nanobodies Market Generated Opportunities, Future Scope - openPR
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
Nanobodies Market reached US$ 502.60 million in 2023 and - openPR
Biotech Stocks Surging in September - AccessWire
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
GT Biopharma files automatic mixed securities shelf - MSN
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
Gain Therapeutics Advances Parkinson's Treatment: Phase 1b Trial Approved After Promising Early Results - StockTitan
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
GTBP Stock Hits 52-Week Low at $1.92 Amid Market Challenges - Investing.com
New Data Supports BLA Package - Streetwise Reports
Contrasting GT Biopharma (NASDAQ:GTBP) and Allakos (NASDAQ:ALLK) - Defense World
The Goodyear Tire & Rubber Company (NASDAQ:GT) Shares Acquired by Fmr LLC - Defense World
BeautyHealth Releases 2024 Skintuition Report - Quantisnow
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Nanobodies Market Is Booming Worldwide 2024-2031 | Merck KGaA, - openPR
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
FDA Decision on Drug for Bone Marrow Due Early 2025 - Streetwise Reports
Roth Capital Weighs in on GT Biopharma FY2024 Earnings - Defense World
United States Nanobodies Market Size, Trends, Growth, - openPR
Gt Biopharma Inc (GTBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
자본화:
|
볼륨(24시간):